Payment overview · 2025
General Payments
$667.44
27 reported records · 9 companies
Healthcare provider profile · identity verified
Ernestine A Wright, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · TIMONIUM, MD · NPI 1306896006
Verified facts
What the public records show
CMS Open Payments records show Ernestine A Wright, M.D. received $667.44 in general payments during 2025 across 27 reported records.
Novo Nordisk Inc accounted for 28.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $188.31 | 28.2% | 10 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $141.42 | 21.2% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $127.78 | 19.1% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $70.84 | 10.6% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $46.15 | 6.9% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $42.45 | 6.4% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.85 | 2.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.52 | 2.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.12 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $549.59 | 25 |
| Education | $117.85 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $188.31 | 10 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $188.31 | 10 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $127.78 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $50.94 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $42.45 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $42.42 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $23.60 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $22.55 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.55 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.90 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.52 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.52 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 159 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 62 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 88 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 122 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
62 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
62 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
88 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
122 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
159 | 36 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
23 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 649 | 196 |
| Atorvastatin Calcium | Atorvastatin Calcium | 531 | 171 |
| Metoprolol Succinate | Metoprolol Succinate | 383 | 116 |
| Lisinopril | Lisinopril | 295 | 91 |
| Gabapentin | Gabapentin | 269 | 84 |
| Prednisone | Prednisone | 262 | 146 |
| Metformin Hcl | Metformin Hcl | 232 | 80 |
| Levothyroxine Sodium | Levothyroxine Sodium | 228 | 75 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 225 | 67 |
| Fluticasone Propionate | Fluticasone Propionate | 215 | 70 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 209 | 87 |
| Oxycodone Hcl | Oxycodone Hcl | 194 | 21 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 190 | 136 |
| Omeprazole | Omeprazole | 188 | 63 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 185 | 71 |
| Montelukast Sodium | Montelukast Sodium | 178 | 69 |
| Hydrochlorothiazide | Hydrochlorothiazide | 170 | 55 |
| Furosemide | Furosemide | 162 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 160 | 60 |
| Eliquis | Apixaban | 159 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 153 | 62 |
| Azithromycin | Azithromycin | 150 | 103 |
| Nifedipine Er | Nifedipine | 148 | 42 |
| Losartan Potassium | Losartan Potassium | 146 | 47 |
| Famotidine | Famotidine | 145 | 56 |
| Trazodone Hcl | Trazodone Hcl | 137 | 48 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 128 | 59 |
| Diclofenac Sodium | Diclofenac Sodium | 126 | 53 |
| Tramadol Hcl | Tramadol Hcl | 126 | 35 |
| Ozempic | Semaglutide | 122 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 111 | 44 |
| Carvedilol | Carvedilol | 108 | 37 |
| Simvastatin | Simvastatin | 108 | 39 |
| Potassium Chloride | Potassium Chloride | 107 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 105 | 34 |
| Atenolol | Atenolol | 99 | 33 |
| Cefuroxime | Cefuroxime Axetil | 99 | 81 |
| Methylprednisolone | Methylprednisolone | 96 | 77 |
| Allopurinol | Allopurinol | 94 | 31 |
| Metformin Hcl Er | Metformin Hcl | 93 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 90 | 30 |
| Mounjaro | Tirzepatide | 88 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 86 | 30 |
| Januvia | Sitagliptin Phosphate | 85 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 78 | 14 |
| Meloxicam | Meloxicam | 77 | 38 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 75 | 26 |
| Lorazepam | Lorazepam | 74 | 30 |
| Sertraline Hcl | Sertraline Hcl | 70 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 67 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 62 | 46 |
| Jardiance | Empagliflozin | 62 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 62 | 25 |
| Meclizine Hcl | Meclizine Hcl | 61 | 26 |
| Candesartan Cilexetil | Candesartan Cilexetil | 60 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 60 | 18 |
| Metronidazole | Metronidazole | 60 | 37 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 60 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 57 | 18 |
| Donepezil Hcl | Donepezil Hcl | 56 | 21 |
| Glimepiride | Glimepiride | 55 | 19 |
| Bupropion Xl | Bupropion Hcl | 54 | 23 |
| Fluconazole | Fluconazole | 54 | 42 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 53 | 31 |
| Glipizide | Glipizide | 53 | 17 |
| Fluocinonide | Fluocinonide | 52 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | 14 |
| Xarelto | Rivaroxaban | 52 | 11 |
| Colchicine | Colchicine | 51 | 17 |
| Valsartan | Valsartan | 51 | 13 |
| Ezetimibe | Ezetimibe | 49 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 47 | 36 |
| Spironolactone | Spironolactone | 47 | 19 |
| Baclofen | Baclofen | 45 | 25 |
| Clonidine Hcl | Clonidine Hcl | 45 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | 20 |
| Ibuprofen | Ibuprofen | 43 | 18 |
| Breo Ellipta | Fluticasone/Vilanterol | 42 | 15 |
| Irbesartan | Irbesartan | 42 | 13 |
| Diazepam | Diazepam | 41 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 41 | suppressed |
| Pregabalin | Pregabalin | 41 | 18 |
| Promethazine Hcl | Promethazine Hcl | 40 | 12 |
| Valacyclovir | Valacyclovir Hcl | 40 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 28 |
| Mirtazapine | Mirtazapine | 39 | 11 |
| Alprazolam | Alprazolam | 37 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | suppressed |
| Trulicity | Dulaglutide | 37 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | 12 |
| Ondansetron Odt | Ondansetron | 35 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 34 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 34 | 21 |
| Glipizide Er | Glipizide | 34 | 11 |
| Labetalol Hcl | Labetalol Hcl | 34 | suppressed |
| Lactulose | Lactulose | 34 | 14 |
| Naproxen | Naproxen | 34 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 34 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | 14 |
| Methocarbamol | Methocarbamol | 32 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Lidocaine | Lidocaine | 30 | 15 |
| Mupirocin | Mupirocin | 30 | 25 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Cephalexin | Cephalexin | 29 | 24 |
| Latanoprost | Latanoprost | 29 | suppressed |
| Nystatin | Nystatin | 29 | 17 |
| Topiramate | Topiramate | 28 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 25 | 13 |
| Levofloxacin | Levofloxacin | 25 | 23 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 25 | suppressed |
| Cefdinir | Cefdinir | 24 | 22 |
| Ramipril | Ramipril | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 23 |
| Sucralfate | Sucralfate | 23 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 20 | 16 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Pentoxifylline | Pentoxifylline | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 18 | 17 |
| Constulose | Lactulose | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 16 | suppressed |
| Paroxetine Er | Paroxetine Hcl | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Ciclopirox | Ciclopirox | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 12 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Azathioprine | Azathioprine | 11 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 11 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Junel Fe | Norethindrone-E.Estradiol-Iron | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $667.44 · 27 records | Novo Nordisk Inc | AIRSUPRA, Cologuard Collection Kit, ELIQUIS, FARXIGA, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, Ozempic, Rybelsus, VOQUEZNA, VYNDAQEL, Veozah, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error